Head-To-Head Comparison: Miravant Medical Technologies (OTCMKTS:MRVT) vs. Silence Therapeutics (NASDAQ:SLN)

Silence Therapeutics (NASDAQ:SLN) and Miravant Medical Technologies (OTCMKTS:MRVT) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

Insider & Institutional Ownership

98.7% of Silence Therapeutics shares are owned by institutional investors. 4.1% of Silence Therapeutics shares are owned by insiders. Comparatively, 17.1% of Miravant Medical Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and target prices for Silence Therapeutics and Miravant Medical Technologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	2	0	5	0	2.43
Miravant Medical Technologies	0	0	0	0	0.00

Silence Therapeutics presently has a consensus target price of $32.60, indicating a potential upside of 388.02%. Given Silence Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Silence Therapeutics is more favorable than Miravant Medical Technologies.

Profitability

This table compares Silence Therapeutics and Miravant Medical Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-254.25%	-61.76%	-36.62%
Miravant Medical Technologies	N/A	N/A	N/A

Valuation & Earnings

This table compares Silence Therapeutics and Miravant Medical Technologies”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$43.26 million	7.29	-$45.31 million	($1.35)	-4.95
Miravant Medical Technologies	N/A	N/A	N/A	N/A	N/A

Miravant Medical Technologies has lower revenue, but higher earnings than Silence Therapeutics.

Summary

Silence Therapeutics beats Miravant Medical Technologies on 5 of the 9 factors compared between the two stocks.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

About Miravant Medical Technologies

Miravant Medical Technologies Inc. operates as a pharmaceutical research and development company. The company develops PhotoPoint, a photodynamic therapy that responds to light destroying cancerous cells; and manufactures light producing and light delivery devices. Its products include PHOTREX for the treatment of wet age-related macular degeneration or AMD; MV9411, a photoreactive drug for the treatment of plaque psoriasis; MV0633 for the treatment of atherosclerosis, atherosclerotic vulnerable plaque, and restenosis; MV2101 for the treatment of vascular access graft disease in hemodialysis patients; and MV6401 for the treatment of solid tumors. Miravant Medical Technologies Inc. was formerly known as PDT, Inc. and changed its name to Miravant Medical Technologies Inc. in September 1997. The company was founded in 1989 and is headquartered in Santa Barbara, California.